Credit and interest ratesnegative · 4 filings
“The net tax benefit for the quarter-to-date period was primarily related to pre-tax losses due to acquisition amortization and interest expense.”10-Q · Apr 9, 2026 ↗
Neogen Corporation
NEOG
Market read
Neogen Corporation's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 19 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.
Company+0.1% todayVolume comparison unavailable
Market group0 of 19 activeConsumer Health & Finance · unavailable
Disclosed network0 of 1 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- NEOG's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if NEOG's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 19 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- NEOG's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations318
Usable filing statements111
Verified relationships1
Evidence supporting the case
- Operating margin changed +116.1 percentage points in the latest annual period.
- Net margin changed +121.1 percentage points in the latest annual period.
Evidence challenging the case
- Latest annual revenue changed -2.7% year over year.
- Credit and interest rates has repeated adverse evidence across 4 filings.
- Restructuring and cost reductions has repeated adverse evidence across 4 filings.
- Tariffs and trade policy has repeated adverse evidence across 4 filings.
Questions before a position
- EV/sales is 197% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 9, 2026
11.926m+5.3%12m+111.6%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2022-05-31$527.2M+12.5%$0.45+0.8%
2023-05-31$822.4M+56.0%$-0.12—
2024-05-31$924.2M+12.4%$-0.04+14.6%
2025-05-31$894.7M-3.2%$-5.03+0.2%
2026-05-31$870.4M-2.7%$-0.04+0.3%
What management says matters
Persistent and emerging business drivers
Foreign exchangemixed · 4 filings
“The increase during the three months ended February 28, 2026 was primarily driven by increases in countries within Europe and favorable foreign exchange rate impact, partially offset by a decline in the divested Cleaners and Disinfectants sales.”10-Q · Apr 9, 2026 ↗
Restructuring and cost reductionsnegative · 4 filings
“The increase was primarily due to lower operating costs in the current year, which is the result of the prior year's restructuring actions incurred for the genomics business.”10-Q · Apr 9, 2026 ↗
Tariffs and trade policymixed · 4 filings
“The decline in the business was driven by lower rodent control and veterinary instrument sales, which have been impacted by tariffs and supply constraints.”10-Q · Apr 9, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 3.0× · EV/sales 3.7×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
11.92+0.1% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 9 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for NEOG. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for NEOG. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind NEOG
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ZTSZoetis Inc.partnerApr 9, 2026 ▾
“On March 2, 2026, we announced that we had entered into a definitive agreement to sell our Genomics business to Zoetis Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
NEOG is currently a Follower in the organic co-movement group Consumer Health & Finance. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for NEOG; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.